- Earth Science Tech, a strategic holding company in the healthcare, pharmacy, and telemedicine sector, is distinct from other OTC listed companies based on its record of strong results, hard real estate assets, vertical integration, and robust corporate structure
- The company has reported year-over-year growth in revenue and gross profits since fiscal year 2024, progress attributable to careful strategic and complementary investments and acquisitions, which have not added debt to its balance sheet
- Its acquisition of Avenvi created a subsidiary that develops, manages, and finances real estate and owns property that houses ETST’s Texas pharmacy
Investopedia lists the lack of reliable information about listed companies as one of the primary risks of OTC stocks. This, according to the article, makes it difficult for investors to evaluate and ascertain the “realistic potential” of these stocks (https://ibn.fm/4qcql). However, Earth Science Tech (OTC: ETST) overcomes this long-held stigma attached to OTC stocks, emerging as an anomaly given its strong financial results (and timely filings), a robust corporate structure, vertical integration, and hard real estate assets, which, combined, set it apart from the conventional, risk-yielding attributes of “penny stocks.”
Earth Science Tech’s most recent annual report for the fiscal year ended March 31, 2026 (“FY2026”), tells the story of year-over-year growth. The company logged $35.7 million in revenue in FY2026, up from $33.1 million in FY2025 (https://ibn.fm/gmnx1) and $11.95 million in FY2024 (https://ibn.fm/cUtl7). Its gross profit grew to $25.5 million in FY 2026 from $24.3 million and $7.8 million in FY2025 and FY2024, respectively.
According to Giorgio R. Saumat, CEO and Chairman of the Board, the fiscal 2026 results reflected the meaningful progress the company has “made over the last several years to build a business that is durable, self-sustaining, and positioned for long-term growth.” Part of this progress can be attributed to the company’s real estate asset aggregation under its Avenvi subsidiary as well as prudent cash management and capital allocation.
Real Estate Asset Aggregation
Earth Science Tech acquired Avenvi, a dynamic real estate company, in fiscal 2025. Avenvi’s Financial Services division offers a wide range of financial products and guidance to customers to support homeownership and refinancing. Relatedly, Avenvi leverages its financial expertise to manage investment activities for ETST.
Avenvi’s real estate development division manages and builds residential and commercial property; it owns the property housing ETST’s Mister Meds pharmacy in Texas. Avenvi currently has a portfolio of 13 properties, underscoring its strategic status as a distinct vehicle for hard-asset wealth generation. Through its operations and investments in real estate and asset management activities, Avenvi supports ETST’s healthcare operations.
Financial Prudence
In fiscal 2026, Earth Science Tech recorded several milestones that signal financial prudence, cash management, and strategic capital allocation. ETST permitted and built out its first residential property at Avenvi without adding any debt to its balance sheet. Additionally, the company acquired DOConsultation and Villas Health, redesigned and rebuilt its proprietary tech stack, relaunched MyOnlineConsultation, accelerated marketing efforts at its Peaks subsidiary, and built and operationalized the Texas location of its Mister Meds compounding pharmacy from the ground up, all without adding any debt. (The Texas property is owned and managed by Avenvi.)
This financial prudence enabled the company to enter the current financial year “in a position of real financial strength,” according to Mr. Saumat’s letter to shareholders (https://ibn.fm/kZnaN). “Looking ahead, our core focus remains on optimizing the operational frameworks of our holdings to support scalable, sustainable expansion.”
For more information, visit the company’s website at www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
